In this issue:
Survival benefit to adjuvant celecoxib in PIK3CA-mutated colon cancer
High response rates to neoadjuvant immunotherapy in localised dMMR colon cancer
Sotorasib–panitumumab promising for chemo-refractory KRAS G12C-mutated mCRC
Anti-PD-1, HDAC inhibitor and anti- VEGF for MSS/pMMR mCRC
Negative hyperselection using ctDNA may inform front-line use of anti-EGFR
Features of microsatellite instability in pMMR CRC
SCARCE: no benefit to atezolizumab + chemo in anal cancer
Nivolumab + relatlimab beneficial in previously treated MSI-H/dMMR mCRC
Immunoscore prognostic for DFS in stage 3 CRC
Primary tumour resection vs chemotherapy for CRC with unresectable metastases
Please login below to download this issue (PDF)